Global Blood Therapeutics is focused on developing novel, orally-available therapeutics for chronic blood diseases. The company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options. Learn More

Spotlight on Sickle Cell Disease 

Global Blood Therapeutics’ lead program is in sickle cell disease (SCD), which impacts approximately 100,000 patients in the U.S. and more than 7 million worldwide. There are very limited treatment options for patients with SCD, and none that address the underlying cause of the disease.

Learn More

Recent News

1.12.15

Global Blood Therapeutics Announces First Cohort Dosed in Phase I/II Trial of GBT440 in Sickle Cell Disease
Read More >>


1.8.15

Willie L. Brown, Jr. Joins the Board of Directors of Global Blood Therapeutics
Read More >>


1.6.15

Global Blood Therapeutics Completes $48 Million Series B Financing
Read More >>


1.5.15

Global Blood Therapeutics to Present at Upcoming Investor Conferences
Read More >>


12.8.14

Global Blood Therapeutics’ GBT440 Demonstrates Ability to Positively Impact Fundamental Sickle Cell Disease (SCD) Processes in Studies Presented at 2014 American Society of Hematology (ASH) Conference
Read More >>